398 related articles for article (PubMed ID: 37286304)
1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
Kelly RJ; Bever K; Chao J; Ciombor KK; Eng C; Fakih M; Goyal L; Hubbard J; Iyer R; Kemberling HT; Krishnamurthi S; Ku G; Mordecai MM; Morris VK; Paulson AS; Peterson V; Shah MA; Le DT
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286304
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
[TBL] [Abstract][Full Text] [Related]
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Kluger H; Barrett JC; Gainor JF; Hamid O; Hurwitz M; LaVallee T; Moss RA; Zappasodi R; Sullivan RJ; Tawbi H; Sharon E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918224
[TBL] [Abstract][Full Text] [Related]
9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
10. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
[TBL] [Abstract][Full Text] [Related]
11. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Galsky MD; Balar AV; Black PC; Campbell MT; Dykstra GS; Grivas P; Gupta S; Hoimes CJ; Lopez LP; Meeks JJ; Plimack ER; Rosenberg JE; Shore N; Steinberg GD; Kamat AM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266883
[TBL] [Abstract][Full Text] [Related]
12. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
13. Current status of immunotherapy in gastrointestinal malignancies.
Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
[TBL] [Abstract][Full Text] [Related]
14. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ; Davar D; Andtbacka RH; Bhardwaj N; Brody JD; Chesney J; Coffin R; de Baere T; de Gruijl TD; Fury M; Goldmacher G; Harrington KJ; Kaufman H; Kelly CM; Khilnani AD; Liu K; Loi S; Long GV; Melero I; Middleton M; Neyns B; Pinato DJ; Sheth RA; Solomon SB; Szapary P; Marabelle A
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641350
[TBL] [Abstract][Full Text] [Related]
15. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Gastrointestinal Malignancies.
Surana R; Pant S
Adv Exp Med Biol; 2021; 1342():259-272. PubMed ID: 34972968
[TBL] [Abstract][Full Text] [Related]
17. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers.
Collienne M; Loghmani H; Heineman TC; Arnold D
Future Oncol; 2022 Aug; 18(26):2871-2878. PubMed ID: 35796248
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
19. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Zayac A; Almhanna K
Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
[TBL] [Abstract][Full Text] [Related]
20. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]